<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549496</url>
  </required_header>
  <id_info>
    <org_study_id>OHRI-BCP-CCB-2012</org_study_id>
    <nct_id>NCT01549496</nct_id>
  </id_info>
  <brief_title>A Drug Interaction Study of Boceprevir in Combination With Amlodipine or Diltiazem in Healthy Volunteers</brief_title>
  <official_title>A Drug Interaction Study Investigating the Effect of Boceprevir on the Pharmacokinetics of the Calcium Channel Blockers Amlodipine and Diltiazem and Vice Versa in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetic interactions between the&#xD;
      hepatitis C NS3 protease inhibitor boceprevir and the calcium channel blockers amlodipine and&#xD;
      diltiazem in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Investigator left this hospital&#xD;
  </why_stopped>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetics</measure>
    <time_frame>7 days</time_frame>
    <description>AUC, Cmax, Cmin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of participants with adverse events</measure>
    <time_frame>29 days</time_frame>
    <description>description and frequency of adverse events for all participants during the study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>boceprevir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>boceprevir 800 mg tid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>amlodipine 2.5 mg QD</description>
    <arm_group_label>boceprevir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diltiazem</intervention_name>
    <description>diltiazem 120 mg qd</description>
    <arm_group_label>boceprevir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to sign informed consent prior to any study-related activities.&#xD;
&#xD;
          2. Male or female subjects between 18 and 65 years of age inclusive.&#xD;
&#xD;
          3. Healthy, i.e. not suffering from a relevant acute or chronic illness.&#xD;
&#xD;
          4. Body Mass Index (BMI) of 17.5 to 31 kg/m2; and a total body weight &gt; 50 kg (110 lbs).&#xD;
&#xD;
          5. Acceptable medical history, physical examination, and 12-lead ECG at screening.&#xD;
&#xD;
          6. Acceptable laboratory values that indicate adequate baseline organ function at&#xD;
             screening visit.&#xD;
&#xD;
          7. Willing to stop using any herbal or natural health products for 2 weeks prior to and&#xD;
             during the study including: Grapefruit, grapefruit juice, St. John's Wort.&#xD;
&#xD;
          8. Willingness to abstain from alcohol use for 3 days prior to and during the study.&#xD;
&#xD;
          9. Female subject is either not of childbearing potential, defined as postmenopausal for&#xD;
             at least 1 year or surgically sterile (bilateral tubal ligation, bilateral&#xD;
             oophorectomy or hysterectomy), or is of childbearing potential and practicing one of&#xD;
             the following methods of birth control:&#xD;
&#xD;
               -  Condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD)&#xD;
&#xD;
               -  A vasectomized partner&#xD;
&#xD;
               -  Total abstinence from sexual intercourse&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have serological evidence of exposure to HIV or HCV.&#xD;
&#xD;
          2. Known allergies to any of the study medications.&#xD;
&#xD;
          3. Female subjects of childbearing potential who:&#xD;
&#xD;
               -  Has a positive urine pregnancy test at screening.&#xD;
&#xD;
               -  Is not willing to use a reliable method of barrier contraception during the&#xD;
                  study.&#xD;
&#xD;
               -  Using only oral contraceptive as a birth control method.&#xD;
&#xD;
               -  Is breastfeeding.&#xD;
&#xD;
          4. Inability to adhere to protocol.&#xD;
&#xD;
          5. Use of any medications (2 weeks prior to or during the study) other than occasional&#xD;
             use of acetaminophen.&#xD;
&#xD;
          6. Female subjects using contraceptives that contain drospirenone.&#xD;
&#xD;
          7. Subjects that are currently smoking.&#xD;
&#xD;
          8. Subjects with hypertension or heart disease requiring medical treatment.&#xD;
&#xD;
          9. Any condition possibly affecting drug absorption (e.g., gastro intestinal disorder).&#xD;
&#xD;
         10. Patients may be excluded from the study for other reasons, at the investigator's&#xD;
             discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles la Porte, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Investigation Unit, Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.ohri.ca/ciu/</url>
    <description>Info on Clinical Investigation Unit</description>
  </link>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>March 1, 2012</study_first_submitted>
  <study_first_submitted_qc>March 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <last_update_submitted>January 7, 2015</last_update_submitted>
  <last_update_submitted_qc>January 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>boceprevir</keyword>
  <keyword>hypertension</keyword>
  <keyword>amlodipine</keyword>
  <keyword>diltiazem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

